Wells Messersmith
Professor and Cancer Center Director
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (32)
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Oligometastatic pancreatic cancer is a distinct clinical entity with limited metastatic burden. This unique subset of patients harbor a favorable tumor biology and potentially better prognosis compared to widespread metastatic disease. This review explores definitions of oligometastatic pancreatic cancer and the current state of management, including systemic therapy, surgery, and locoregional techniques. While there are few randomized clinical trials directing the management of oligometastatic pancreatic cancer, we provide insights into the treatment challenges, evolving therapeutic approaches, and future directions for this unique subset of patients.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Importance The effect of adjuvant chemotherapy following resection of pancreatic adenocarcinoma after preoperative (m)FOLFIRINOX (combination leucovorin calcium [folinic acid], fluorouracil, irinotecan hydrochloride, and oxaliplatin in full or modified dosing) chemotherapy on overall survival (OS) is unclear because current studies do not account for the number of cycles of preoperative chemotherapy and adjuvant chemotherapy regimen. Objective To investigate the association of adjuvant chemotherapy following resection of pancreatic adenocarcinoma after preoperative (m)FOLFIRINOX with OS, taking into account the number of cycles of preoperative chemotherapy and adjuvant chemotherapy regimen. Design, Setting, and Participants This retrospective cohort study included patients with localized pancreatic adenocarcinoma treated with 2 to 11 cycles of preoperative (m)FOLFIRINOX followed by resection across 48 centers in 20 countries from 2010 to 2018. Patients who died within 3 months after surgery were excluded (landmark). Data were analyzed from February 1 to December 31, 2023. Exposures Preoperative (m)FOLFIRINOX chemotherapy followed by resection and eventually followed by adjuvant chemotherapy. Main Outcomes and Measures The primary outcome was OS, calculated from the 3-month landmark. Cox regression analysis, including interaction analyses, was performed to investigate the association of adjuvant chemotherapy with OS. Results Overall, 767 patients were included after resection of pancreatic adenocarcinoma (median [IQR] age, 62 [55-67] years; 404 [52.7%] male). Adjuvant chemotherapy was independently associated with prolonged OS (hazard ratio [HR], 0.66; 95% CI, 0.49-0.87), confirmed by adjusted OS curves. The interaction analysis to assess estimated treatment effect across subgroups was not statistically significant. The forest plot and interaction test suggest that the association of adjuvant chemotherapy was lower among patients receiving 8 or more cycles of preoperative (m)FOLFIRINOX, those who had radiological response, and those with ypN0 disease. Compared to no adjuvant chemotherapy, both adjuvant (m)FOLFIRINOX (HR, 0.57; 95% CI, 0.40-0.80) and other multiagent adjuvant regimens (HR, 0.61; 95% CI, 0.41-0.92) were associated with prolonged OS, whereas single-agent adjuvant chemotherapy was not (HR, 0.75; 95% CI, 0.55-1.03). Conclusions and Relevance In this cohort study, adjuvant (m)FOLFIRINOX and other multiagent chemotherapy regimens were associated with improved OS following resection of localized pancreatic adenocarcinoma after preoperative (m)FOLFIRINOX, whereas single-agent adjuvant chemotherapy was not. The impact of adjuvant chemotherapy on OS may be lower in subgroups such as patients with 8 or more preoperative cycles of (m)FOLFIRINOX, those having radiological response, and those with ypN0.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (44)
Shivaani Kummar
Oregon Health & Science University
Matthew Reilley
Assistant Professor
University of Virginia School of Medicine
Mariano Ponz-Sarvise
Universidad de Navarra
Oliver Strobel
Head of Department, Professor of Visceral Surgery
Medical University of Vienna
Junxiao Hu
Assistant Professor
University of Colorado Anschutz Medical Campus
Alessandro Zerbi
Director
Humanitas University
Yuan-Haw Andrew Wu
Johns Hopkins University
Ammar Javed
Assistant Professor
NYU Langone Health
Christopher Lieu
Associate Professor
University of Denver
Niharika Mettu
Duke University
Laura Pike
Sr. Professional Research Assistant
University of Colorado Anschutz Medical Campus
Apostolia M. Tsimberidou
Professor
The University of Texas MD Anderson Cancer Center
Hiroyuki Ishida
Assistant Professor
Kansai Medical University
Judith D. Goldberg
Professor of Population Health and Environmental Medicine
NYU School of Medicine
Maria João Amaral
University of Coimbra
Jennifer Diamond
Professor of Medicine with Tenure
University of Colorado Anschutz Medical Campus
Gennaro Nappo
Humanitas University
Anne Noonan
Professor
The Ohio State University Comprehensive Cancer Center
Michael Gordon
Chief Medical Officer
-
Adrie van Bokhoven
Associate Professor
University of Colorado
Ian Chau
Royal Marsden Hospital Sutton
Isao Matsumoto
Professor
University of Tsukuba
Todd Pitts
-
Robert Lentz
Assistant Professor
University of Colorado Cancer Center
Knut Jørgen Labori
Professor
Oslo University Hospital
Hannah Robinson
Assistant Professor
The Ohio State University Wexner Medical Center
David S. Hong
The University of Texas MD Anderson Cancer Center
Sunnie S. Kim
University of Colorado Anschutz Medical Campus
Michael J. Overman
-
Nigel Jamieson
University of Glasgow
Daniel LaBarbera
Professor and Director, The CU Anschutz Center for Drug Discovery
University of Colorado Anschutz Medical Campus
Teresa Macarulla
Head of Gastrointestinal and Endocrine Tumor Unit
Hospital Clínic de Barcelona
Andrew Coveler
Fred Hutchinson Cancer Research Center
Howard S Hochster
Rutgers University
Nataliya Uboha
Associate Professor
University of Wisconsin-Madison Carbone Cancer Center
Kirk C. Hansen
Prof
University of Colorado Boulder
Jozef Urdzik
Uppsala University
Nick Pavlakis
Professor
University of Sydney
Alexis Leal
Assistant Professor of Medicine
University of Colorado Anschutz Medical Campus
Christos Fountzilas
Associate Professor
Roswell Park Comprehensive Cancer Center
Elizabeth Pando
Universitat Autònoma de Barcelona (UAB)
Hector Esquer
Senior Research Scientist
University of Colorado Anschutz Medical Campus
Julie Lang
Associate Research Professor
University of Colorado Anschutz Medical Campus
Daisuke Hashimoto
Kansai Medical University
Make your next move.
Prepare your application
Review drafts before you send them.